Skip to main content

Remote Job Finders (RJF)

With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
Psychedelics Space Enters New Era as AbbVie Dives In
Scroll to top